FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
60.3 USD
-0.58 (-0.962%)
About
ceo
Mr. Grant E. Pickering M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://vaxcyte.com
exchange
NASDAQ
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc....
CIK
0001649094
ISIN
US92243G1085
CUSIP
92243G108
Address
825 Industrial Road
Phone
650 837 0111
Country
US
Employee
254
IPO Date
Jun 12, 2020
Summary
CIK
0001649094
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
92243G108
ISIN
US92243G1085
Country
US
Price
60.3
Beta
0.89
Volume Avg.
858.11k
Market Cap
6.56B
Shares
-
52-Week
41.57-82.04
DCF
3.79
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-14.57
P/B
-
Website
https://vaxcyte.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PCVX News
It looks like there's no news available.
